Pathstone Family Office’s Ingevity NGVT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q3
$211K Buy
4,430
+803
+22% +$43.8K ﹤0.01% 1490
2023
Q2
$215K Buy
3,627
+145
+4% +$8.7K ﹤0.01% 1115
2023
Q1
$249K Sell
3,482
-461
-12% -$36.6K ﹤0.01% 996
2022
Q4
$277K Sell
3,943
-2,649
-40% -$187K 0.01% 954
2022
Q3
$400K Sell
6,592
-2
-0% -$134 0.01% 781
2022
Q2
$416K Sell
6,594
-64
-1% -$4.17K 0.01% 656
2022
Q1
$427K Sell
6,658
-23
-0.3% -$1.54K 0.01% 610
2021
Q4
$479K Sell
6,681
-1,979
-23% -$151K 0.01% 573
2021
Q3
$618K Buy
8,660
+2,596
+43% +$205K 0.02% 444
2021
Q2
$493K Buy
+6,064
New +$488K 0.01% 469
2017
Q2
– Sell
-4
Closed – – 556
2017
Q1
$0 Buy
+4
New +$226 ﹤0.01% 606

Other funds holding NGVT

Pathstone Family Office's NGVT Position: Q3 2023 in Review

Pathstone Family Office increased its Ingevity (NGVT) stake by 22% in Q3 2023, buying an estimated $43.8K and bringing the position to 4,430 shares worth $211K. The position accounts for ﹤0.01% of the portfolio, ranked #1490.

Pathstone Family Office first reported a position in NGVT in Q1 2017 and has held it in 11 quarters since. The position peaked at $618K in Q3 2021. 258 funds tracked by Wall St. Rank hold NGVT as of Q3 2023.

  • Pathstone Family Office held 4,430 shares of Ingevity worth $211K as of Q3 2023.
  • Pathstone Family Office bought 803 Ingevity shares in Q3 2023, an estimated $43.8K.
  • Ingevity made up ﹤0.01% of Pathstone Family Office's portfolio in Q3 2023, its #1490 holding.
  • Pathstone Family Office first reported a position in Ingevity in Q1 2017 and has held it in 11 quarters since.
  • Pathstone Family Office's Ingevity position peaked at $618K in Q3 2021.
  • 258 funds tracked by Wall St. Rank held Ingevity as of Q3 2023.

Based on Pathstone Family Office's 13F filing for Q3 2023, filed 8 Nov 2023.